Semax Research Peptide (ACTH4-7-PGP)
Lyophilized Format • ≥99% HPLC Purity • Ships in 1–2 Business Days • U.S. Warehouses
Semax (ACTH4-7-PGP, CAS 80714-61-0) is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, developed as a structurally modified analog of the endogenous regulatory peptide ACTH(4-10) (Met-Glu-His-Phe-Arg-Trp-Gly) by the Institute of Molecular Genetics of the Russian Academy of Sciences, supplied by Nextday Peptides in lyophilized format for laboratory and analytical research applications. Semax retains the ACTH(4-7) core sequence but replaces the C-terminal Arg-Trp-Gly with Pro-Gly-Pro to enhance metabolic stability, and is entirely devoid of adrenocorticotropic hormonal activity. It is studied as a research tool for investigating BDNF signaling, dopaminergic and serotonergic pathway modulation, neurotrophin expression, and neuroprotective mechanisms in controlled preclinical experimental systems. Each vial is independently verified to ≥99% HPLC purity with a Certificate of Analysis available on request. For scientific research use only.
Compound Specifications
| Compound Name | Semax / ACTH4-7-PGP / ACTH(4-7)-Pro-Gly-Pro |
| Peptide Sequence | Met-Glu-His-Phe-Pro-Gly-Pro |
| Amino Acids | 7 (Heptapeptide) |
| Parent Peptide | ACTH(4-10) — endogenous regulatory peptide fragment |
| C-Terminal Modification | Pro-Gly-Pro replaces Arg-Trp-Gly — eliminates ACTH hormonal activity, enhances stability |
| Hormonal Activity | None — entirely devoid of adrenocorticotropic hormonal activity |
| Molecular Formula | C₃₇H₅₁N₉O₁₀S |
| Molecular Weight | 813.94 g/mol |
| CAS Number | 80714-61-0 |
| Form | Lyophilized powder |
| Appearance | White to off-white powder |
| Purity | ≥99% (HPLC verified) |
| Storage | -20°C lyophilized; -20°C stock solutions (1 month); -80°C stock solutions (6 months) |
| Synonyms | ACTH4-7-PGP, Semax peptide, Met-Glu-His-Phe-Pro-Gly-Pro |
Why Research Laboratories Select Semax
Semax is a unique research tool that combines ACTH(4-7) neurotropic core activity with a stability-enhancing Pro-Gly-Pro C-terminal modification — while being entirely free of the adrenocorticotropic hormonal activity associated with full-length ACTH. This separation of neurotropic activity from hormonal effects makes it a clean research tool for studying BDNF signaling, neurotrophin expression modulation, and dopaminergic/serotonergic pathway dynamics in controlled CNS research systems. Additionally Semax has been studied for its ability to form stable Cu²⁺ complexes — making it relevant for copper-mediated neurochemistry and amyloid aggregation research.
- Synthetic ACTH(4-7)-PGP heptapeptide — retains neurotropic core while eliminating adrenocorticotropic hormonal activity
- BBB-penetrable in experimental models — studied for CNS peptide distribution and neurochemistry research
- BDNF pathway modulation — studied for neurotrophin expression regulation in rodent cortical and hippocampal research models
- Dopaminergic and serotonergic system activation studied in preclinical neurochemistry models — Eremin et al. (2005)
- Forms stable Cu²⁺ complexes — studied for copper-induced Aβ aggregation inhibition in Alzheimer’s disease research models
- Proinflammatory gene expression modulation studied in ischemic brain injury rodent models — Dergunova et al. (2021)
- Approved pharmaceutical drug in Russia — extensive published research literature from Russian Academy of Sciences
- Lyophilized format ensures stability and reproducibility across experimental runs
Research Background
Semax was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences by N.F. Myasoedov’s group. Kaplan et al. (1996) published early EEG research demonstrating nootropic-like activity in human volunteers. Eremin et al. (2005) published findings in Neurochemical Research on dopaminergic and serotonergic system activation in rodent models. Sciacca et al. (2022) published findings in ACS Chemical Neuroscience on Semax’s ability to form stable Cu²⁺ complexes and affect copper-induced Aβ aggregation in membrane models. Dergunova et al. (2021) published findings in Molecular Biology on proinflammatory gene suppression in ischemic brain models. All information provided here is for educational and reference purposes only and does not constitute medical or clinical guidance.
Reference sources: Sciacca et al. (2022) — ACS Chemical Neuroscience (PMC) | Eremin et al. (2005) — Neurochemical Research
Shipping & Fulfillment
- Ships from U.S. warehouses — Florida, North Carolina, and California
- Overnight and 2-day shipping available at checkout
- Same-day processing on orders placed before 3:30 PM ET
- Discreet packaging with full tracking provided
- Bulk research orders welcome — contact us for volume pricing
Storage & Handling
- Store lyophilized peptide at -20°C away from light and moisture
- Stock solutions in water: store at -20°C up to 1 month; -80°C up to 6 months
- Aliquot stock solutions into single-use portions to avoid repeated freeze-thaw cycles
- Filter sterilize aqueous solutions with 0.22 μm filter before use in cell-based assays
- Handle using appropriate laboratory safety protocols
- Keep containers sealed when not in use
Frequently Asked Questions
What is Semax?
Semax (ACTH4-7-PGP, CAS 80714-61-0) is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is a modified analog of ACTH(4-10) — the neurotropic fragment of adrenocorticotropic hormone — with a Pro-Gly-Pro C-terminal modification that eliminates adrenocorticotropic hormonal activity while enhancing metabolic stability. Supplied strictly for scientific, analytical, and in-vitro laboratory research use only.
How does Semax differ from ACTH?
Full-length ACTH activates the MC2R adrenal receptor triggering cortisol production. Semax retains only the neurotropic ACTH(4-7) core sequence and replaces the C-terminal Arg-Trp-Gly with Pro-Gly-Pro — making it entirely devoid of adrenocorticotropic hormonal activity while preserving neurotropic and neuroprotective research properties for CNS pathway studies.
How does Semax differ from Selank?
Semax derives from ACTH(4-10) — a neurotropic ACTH fragment — and is primarily studied for dopamine-mediated cognitive pathway, BDNF signaling, and neuroprotective research. Selank derives from tuftsin (IgG Fc fragment) and is primarily studied for GABAergic anxiolytic pathway and neuroimmune signaling research. They are complementary research tools from distinct peptide families targeting different CNS pathway dynamics.
Why is Semax studied in copper-related research?
Semax has been shown to form stable Cu²⁺ complexes via its histidine residue and N-terminal methionine coordination chemistry. Sciacca et al. (2022) published findings in ACS Chemical Neuroscience demonstrating that Semax affects copper-induced Aβ aggregation and amyloid formation in artificial membrane models — making it relevant for copper-mediated neurochemistry and Alzheimer’s disease research.
What purity is your Semax?
Every batch is independently verified to ≥99% HPLC purity. A Certificate of Analysis is available for each lot.
How fast does Nextday Peptides ship?
We ship from U.S. warehouses in Florida, North Carolina, and California. Overnight and 2-day shipping options are available. Orders placed before 3:30 PM ET are processed same day.
Are bulk orders available?
Yes. We accommodate bulk research orders. Contact us directly for volume pricing and availability.
Is this product approved for medical use?
No. This product is for laboratory research use only in the United States. It is not approved by the FDA for any human or veterinary use and is not intended for diagnostic, therapeutic, or clinical applications.
What other compounds does Nextday Peptides carry?
We also carry Selank, DSIP, Thymosin Alpha-1, and BPC-157. View our full research compounds catalog.
For Research Use Only — Not for human or veterinary consumption • Not FDA approved • Supplied by Nextday Peptides for controlled in-vitro laboratory research use only
